APRE
Price
$0.67
Change
-$0.00 (-0.00%)
Updated
Feb 4 closing price
Capitalization
4.63M
Intraday BUY SELL Signals
ENTX
Price
$1.20
Change
-$0.03 (-2.44%)
Updated
Feb 4 closing price
Capitalization
55.03M
50 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

APRE vs ENTX

Header iconAPRE vs ENTX Comparison
Open Charts APRE vs ENTXBanner chart's image
Aprea Therapeutics
Price$0.67
Change-$0.00 (-0.00%)
Volume$436.31K
Capitalization4.63M
Entera Bio
Price$1.20
Change-$0.03 (-2.44%)
Volume$295.48K
Capitalization55.03M
APRE vs ENTX Comparison Chart in %
APRE
Daily Signal:
Gain/Loss:
ENTX
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
APRE vs. ENTX commentary
Feb 05, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APRE is a Hold and ENTX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 05, 2026
Stock price -- (APRE: $0.67 vs. ENTX: $1.20)
Brand notoriety: APRE and ENTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: APRE: 16% vs. ENTX: 148%
Market capitalization -- APRE: $4.63M vs. ENTX: $55.03M
APRE [@Biotechnology] is valued at $4.63M. ENTX’s [@Biotechnology] market capitalization is $55.03M. The market cap for tickers in the [@Biotechnology] industry ranges from $119.38B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

APRE’s FA Score shows that 2 FA rating(s) are green whileENTX’s FA Score has 0 green FA rating(s).

  • APRE’s FA Score: 2 green, 3 red.
  • ENTX’s FA Score: 0 green, 5 red.
According to our system of comparison, APRE is a better buy in the long-term than ENTX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

APRE’s TA Score shows that 4 TA indicator(s) are bullish while ENTX’s TA Score has 4 bullish TA indicator(s).

  • APRE’s TA Score: 4 bullish, 4 bearish.
  • ENTX’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, APRE is a better buy in the short-term than ENTX.

Price Growth

APRE (@Biotechnology) experienced а -12.32% price change this week, while ENTX (@Biotechnology) price change was -18.37% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.81%. For the same industry, the average monthly price growth was +0.47%, and the average quarterly price growth was +32.90%.

Reported Earning Dates

ENTX is expected to report earnings on Mar 27, 2026.

Industries' Descriptions

@Biotechnology (-3.81% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ENTX($55M) has a higher market cap than APRE($4.63M). APRE YTD gains are higher at: -21.454 vs. ENTX (-38.144). ENTX has higher annual earnings (EBITDA): -10.79M vs. APRE (-13.8M). APRE has more cash in the bank: 13.7M vs. ENTX (8.57M). APRE has less debt than ENTX: APRE (0) vs ENTX (211K). ENTX has higher revenues than APRE: ENTX (124K) vs APRE (0).
APREENTXAPRE / ENTX
Capitalization4.63M55M8%
EBITDA-13.8M-10.79M128%
Gain YTD-21.454-38.14456%
P/E RatioN/AN/A-
Revenue0124K-
Total Cash13.7M8.57M160%
Total Debt0211K-
FUNDAMENTALS RATINGS
APRE vs ENTX: Fundamental Ratings
APRE
ENTX
OUTLOOK RATING
1..100
9357
VALUATION
overvalued / fair valued / undervalued
1..100
14
Undervalued
62
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9899
PRICE GROWTH RATING
1..100
9493
P/E GROWTH RATING
1..100
5100
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

APRE's Valuation (14) in the null industry is somewhat better than the same rating for ENTX (62) in the Pharmaceuticals Major industry. This means that APRE’s stock grew somewhat faster than ENTX’s over the last 12 months.

APRE's Profit vs Risk Rating (100) in the null industry is in the same range as ENTX (100) in the Pharmaceuticals Major industry. This means that APRE’s stock grew similarly to ENTX’s over the last 12 months.

APRE's SMR Rating (98) in the null industry is in the same range as ENTX (99) in the Pharmaceuticals Major industry. This means that APRE’s stock grew similarly to ENTX’s over the last 12 months.

ENTX's Price Growth Rating (93) in the Pharmaceuticals Major industry is in the same range as APRE (94) in the null industry. This means that ENTX’s stock grew similarly to APRE’s over the last 12 months.

APRE's P/E Growth Rating (5) in the null industry is significantly better than the same rating for ENTX (100) in the Pharmaceuticals Major industry. This means that APRE’s stock grew significantly faster than ENTX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
APREENTX
RSI
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
85%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 1 day ago
78%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
87%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
86%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
88%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
86%
Advances
ODDS (%)
Bullish Trend 28 days ago
77%
Bullish Trend 29 days ago
80%
Declines
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
APRE
Daily Signal:
Gain/Loss:
ENTX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MNHVF22.751.02
+4.68%
Mowi ASA
HSPOF12.20N/A
N/A
Horizon Space Acquisition I Corp.
PHPPY11.22N/A
N/A
Signify N.V.
WFCNP2.10N/A
N/A
Wells Fargo & Co.
MTMV1.10N/A
N/A
MOTOMOVA INC.

APRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, APRE has been closely correlated with MREO. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if APRE jumps, then MREO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To APRE
1D Price
Change %
APRE100%
-0.49%
MREO - APRE
69%
Closely correlated
-2.73%
BCAB - APRE
66%
Loosely correlated
+11.06%
LENZ - APRE
66%
Loosely correlated
-5.86%
RZLT - APRE
65%
Loosely correlated
-7.62%
CALC - APRE
65%
Loosely correlated
+8.37%
More

ENTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, ENTX has been closely correlated with QNCX. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if ENTX jumps, then QNCX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ENTX
1D Price
Change %
ENTX100%
-2.44%
QNCX - ENTX
70%
Closely correlated
+9.28%
RZLT - ENTX
68%
Closely correlated
-7.62%
LENZ - ENTX
67%
Closely correlated
-5.86%
CALC - ENTX
66%
Loosely correlated
+8.37%
APRE - ENTX
66%
Loosely correlated
-0.49%
More